Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03725059 · ClinicalTrials.gov registry record · Phase 3
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
A Phase 3 study of Breast Cancer, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 1,240
- Enrollment target
- 20
- Study locations
NCT03725059 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 1,240 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03725059, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,240 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. The primary study hypotheses are: 1) pembrolizumab is superior to placebo, both in combination with the protocol-specified neoadjuvant anticancer therapy, as assessed by pathological Complete Response (pCR) rate defined by the local pathologist, and 2) pembrolizumab is superior to placebo (both in combination with the protocol-specified neoadjuvant and adjuvant anticancer therapies) as assessed by Event-Free Survival (EFS) as determined by the investigator. The study is considered to have met its primary objective if pembrolizumab is superior to placebo with respect to either pCR (ypT0/Tis ypN0) or EFS.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab (K)
- DRUG Placebo (P)
- DRUG Paclitaxel (X)
- DRUG Doxorubicin (A)
- DRUG Epirubicin (E)
Study Locations (20)
California
- Cedars Sinai Medical Center Samuel Oschin Comp. Cancer Institute ( Site 0079) - Los Angeles
- El Camino Hospital Cancer Center ( Site 0004) - Mountain View
- Stanford Cancer Center ( Site 0072) - Palo Alto
- UC Davis Comprehensive Cancer Center ( Site 0073) - Sacramento
Illinois
- The University of Chicago Medical Center ( Site 0080) - Chicago
- Orchard Healthcare Research Inc. ( Site 0020) - Skokie
- Midwestern Regional Medical Center, Inc. ( Site 0077) - Zion
Massachusetts
- Massachusetts General Hospital ( Site 0024) - Boston
- MGH - North Shore Cancer Center ( Site 0081) - Danvers
- MGH Newton-Wellesley Hospital's Vernon Cancer Center ( Site 0082) - Newton
Arizona
- Cancer Treatment Centers of America at Western Regional Medical Center ( Site 0001) - Goodyear
- Arizona Oncology Associates PC- HOPE ( Site 8008) - Tucson
Alabama
- Southern Cancer Center, PC ( Site 8003) - Daphne
Colorado
- University of Colorado, Anschutz Cancer Pavilion ( Site 0008) - Aurora
Florida
- Baptist MD Anderson Cancer Center ( Site 0014) - Jacksonville
Georgia
- Southeastern Regional Medical Center, Inc. ( Site 0075) - Newnan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,240 participants |
| Start Date | 2018-12-27 |
| Est. Completion | 2031-01-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03725059
The ClinicalTrials.gov registry entry for NCT03725059 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (56% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab (K) is the first listed.
NCT03725059 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03725059 about?
NCT03725059 is a clinical study titled "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)". The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, huma...
What is the current status of trial NCT03725059?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,240 participants. The study started on 2018-12-27. Estimated completion is 2031-01-24.
What conditions does trial NCT03725059 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03725059?
The interventions under investigation include: Pembrolizumab (K) (BIOLOGICAL), Placebo (P) (DRUG), Paclitaxel (X) (DRUG), Doxorubicin (A) (DRUG), Epirubicin (E) (DRUG).
Who is sponsoring clinical trial NCT03725059?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03725059 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.